H
Henry Wong
Researcher at Bristol-Myers Squibb
Publications - 6
Citations - 266
Henry Wong is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Insulin receptor & Growth factor receptor inhibitor. The author has an hindex of 5, co-authored 6 publications receiving 257 citations.
Papers
More filters
Journal ArticleDOI
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
Mark D. Wittman,Joan M. Carboni,Ricardo M. Attar,Balu Balasubramanian,Praveen Balimane,Patrick J. Brassil,Francis Beaulieu,Chiehying Chang,Wendy Clarke,Janet Dell,Jeffrey Eummer,David B. Frennesson,Marco M. Gottardis,Ann Greer,Steven Hansel,Warren Hurlburt,Bruce L. Jacobson,Subramaniam Krishnananthan,Francis Y. Lee,Aixin Li,Tai-An Lin,Peiying Liu,Carl Ouellet,Xiaopeng Sang,Saulnier Mark G,Stoffan Karen M,Yax Sun,Upender Velaparthi,Henry Wong,Zheng Yang,Kurt Zimmermann,Zoeckler Mary Edson,Dolatrai M. Vyas +32 more
TL;DR: Compound 3 (BMS-536924), a novel small-molecule inhibitor of the insulin-like growth factor receptor kinase with equal potency against the insulin receptor is described.
Journal ArticleDOI
Bicyclic and tricyclic analogues of anthramycin.
TL;DR: Bicyclic analogues 6a', 6f, and 6g were found to be active, indicating that the pyrroline ring of anthramycin is not an absolute necessity for the antitumor activity, and compounds 5, 7a, and 8b were active against P388 leukemia, and they generally appear to be more potent than bicyclic analogueues.
Journal ArticleDOI
Discovery of a Fluoroindolo[2,3-a]carbazole Clinical Candidate with Broad Spectrum Antitumor Activity in Preclinical Tumor Models Superior to the Marketed Oncology Drug, CPT-11†
Saulnier Mark G,Balu Balasubramanian,Byron H. Long,David B. Frennesson,Ruediger Edward H,Kurt Zimmermann,Jeffrey Eummer,Denis R. St. Laurent,Stoffan Karen M,B. Narasimhulu Naidu,Mikael Mahler,Francis Beaulieu,Carol Bachand,Frank Lee,Craig R. Fairchild,Linda K. Stadnick,William C. Rose,Carola Solomon,Henry Wong,Alain Martel,Wright John J,Robert Kramer,David R. Langley,Dolatrai M. Vyas +23 more
TL;DR: A series of fluoroglycosylated fluoroindolocarbazoles was examined with respect to their topoisomerase I activity, cytotoxicity, and selectivity, and the lead clinical candidate, BMS-250749, displays broad spectrum antitumor activity superior to CPT-11 against some preclinical xenograft models, including curative antitumors activity against Lewis lung carcinoma.
Journal ArticleDOI
A total synthesis of chicamycin A a new pyrrolo[1,4]benzodiazepine antitumor agent.
Journal ArticleDOI
Reductive amination of 3-ketoanguidin and antitumor activity of the products.
TL;DR: In in vivo tests against P388 leukemia,mine-containing trichothecanes were prepared by reductive aminations of 3-ketoanguidin and showed an improved activity compared to anguidin though their potency was decreased.